⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901089 | 0.92 | HTR2B (0.48) | — | |
| SCHEMBL1899026 | 0.92 | HTR2B (0.48) | — | |
| SCHEMBL18322736 | 0.91 | HTR2B (0.45) | — | |
| SCHEMBL11099597 | 0.90 | HTR2B (0.47) | — | |
| SCHEMBL18322608 | 0.90 | HTR2B (0.47) | — | |
| SCHEMBL7160459 | 0.90 | HTR2B (0.47) | — | |
| SCHEMBL1299385 | 0.88 | HRH3 (0.46) | — | |
| SCHEMBL3709300 | 0.88 | HTR2B (0.46) | — | |
| Water SCHEMBL29258021 | 0.88 | HTR2B (0.46) | — | |
| SCHEMBL18322692 | 0.87 | HTR2B (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4291555-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-116583521-A | Imidazopyridazine derivatives as IL-17 modulators | UCB生物制药有限责任公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2022173727-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-08-18 | — | — | WO | disclosed |
| US-11358957-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-20200277287-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-09-03 | — | — | US | disclosed |
| US-9598421-B2 | Imidazopyridazine compounds | PFIZER INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160039828-A1 | Imidazopyridazine Compounds | PFIZER INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20110105514-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | disclosed |
| US-20110105514-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | disclosed |
| US-20110105514-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | disclosed |
| WO-2009156951-A2 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-30 | — | — | WO | disclosed |
| CN-1218801-A | Tri-substituted imidazoles, and process of their preparation and using the same and having their pharmic composition | SMITHKLINE BEECHAM CORP (US) | 1999-06-09 | — | — | CN | disclosed |
| CN-1129447-A | Trisubstituted imidazoles having multiple therapeutic effects | SMITHKLINE BEECHAM CORP (US) | 1996-08-21 | — | — | CN | disclosed |